← Leaderboards
Robert J Binder
University Of Pittsburgh At Pittsburgh
$5,876,082
Attributed
$7,158,833
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,158,833 · 8
By mechanism
R01$3,371,556 · 2
T32$1,835,453 · 1
R21$936,419 · 3
U01$547,537 · 1
K22$467,868 · 1
Top collaborators
- Dario Aa Vignali4 shared
- Joel S Greenberger1 shared
- Amitava Mukherjee1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Hassane M Zarour$16,372,397
- Michael T Lotze$5,139,928
- John Munn Kirkwood$15,450,309
- Lisa Helene Butterfield$10,558,896
- Diwakar Davar$3,640,421
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseReceptorMediatingMalignant NeoplasmsTumorPeptidesMolecular ChaperonesImmune ResponseHeat Shock ProteinsAntigen-Presenting CellsT Cell ResponseLigandsKnockout MiceAntigensPathway InteractionsCellsTumor-DerivedImmune SystemLaboratoriesCross-PrimingEventT-LymphocyteCancer ImmunotherapyCross Presentation
Grant awards (23)
Mitigation of hematopoietic acute radiation syndrome (ARS) by inhibition of tyrosine kinase Fgr$547,537
U01 · FY2025 · AI
Cancer Immunology Training Program$469,393
T32 · FY2025 · CA
Co-stimulation of T cell responses to nascent, emerging tumors$176,712
R21 · FY2025 · CA · contact PI
Cancer Immunology Training Program$500,063
T32 · FY2024 · CA
CD91 and cancer immunosurveillance$337,148
R01 · FY2024 · CA · contact PI
Cancer Immunology Training Program$518,655
T32 · FY2023 · CA
CD91 and cancer immunosurveillance$347,794
R01 · FY2023 · CA · contact PI
CD91 and cancer immunosurveillance$347,794
R01 · FY2022 · CA · contact PI
Cancer Immunology Training Program$347,342
T32 · FY2022 · CA
CD91 and cancer immunosurveillance$354,892
R01 · FY2021 · CA · contact PI
CD91 and cancer immunosurveillance$354,892
R01 · FY2020 · CA · contact PI
Heat shock protein gp96 and Treg responses$197,245
R21 · FY2019 · AI · contact PI
Heat shock protein gp96 and Treg responses$194,291
R21 · FY2018 · AI · contact PI
Heat shock proteins and modulation of immune responses$168,141
R21 · FY2017 · CA · contact PI
Heat shock proteins and modulation of immune responses$200,030
R21 · FY2016 · CA · contact PI
Role of CD91 and its ligands in immune response$308,784
R01 · FY2013 · AI · contact PI
Role of CD91 and its ligands in immune response$328,493
R01 · FY2012 · AI · contact PI
Role of CD91 and its ligands in immune response$328,493
R01 · FY2011 · AI · contact PI
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy$160,023
K22 · FY2011 · CA · contact PI
Role of CD91 and its ligands in immune response$331,811
R01 · FY2010 · AI · contact PI
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy$155,916
K22 · FY2010 · CA · contact PI
Role of CD91 and its ligands in immune response$331,455
R01 · FY2009 · AI · contact PI
Role for alpha2-Macroglobulin in Immune Responses and Cancer Immunotherapy$151,929
K22 · FY2009 · CA · contact PI